Loading...
ABMD logo

Abiomed, Inc.NasdaqGS:ABMD Stock Report

Market Cap US$17.2b
Share Price
n/a
My Fair Value
n/a
1Y8.2%
7D0.005%
1D
Portfolio Value
​
View

Abiomed, Inc.

NasdaqGS:ABMD Stock Report

Market Cap: US$17.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abiomed (ABMD) Stock Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. More details

ABMD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 13.08% per year

Earnings grew by 78.9% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 2.5% per year for the next 3 years

Volatile share price over the past 3 months

Large one-off items impacting financial results


ABMD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Abiomed, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Abiomed
Historical stock prices
Current Share PriceUS$381.02
52 Week HighUS$381.99
52 Week LowUS$219.85
Beta1.4
1 Month Change0.86%
3 Month Change55.18%
1 Year Change8.18%
3 Year Change125.10%
5 Year Change103.31%
Change since IPO6,385.45%

Recent News & Updates

Seeking Alpha • Oct 17

Abiomed's Impella low profile sheath gets FDA clearance

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed's (NASDAQ:ABMD) Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr, the company said in a statement on Monday. Abiomed added that due to its smaller size and other advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, and reduce procedural steps. The company said that it will begin a phased roll-out of the Impella Low Profile Sheath this quarter. The heart pump Impella CP with SmartAssist is approved to treat certain patients with advanced heart failure who are undergoing percutaneous coronary interventions, such as stenting or balloon angioplasty, to reopen blocked coronary arteries, according to the company.

Recent updates

Seeking Alpha • Oct 17

Abiomed's Impella low profile sheath gets FDA clearance

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed's (NASDAQ:ABMD) Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr, the company said in a statement on Monday. Abiomed added that due to its smaller size and other advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, and reduce procedural steps. The company said that it will begin a phased roll-out of the Impella Low Profile Sheath this quarter. The heart pump Impella CP with SmartAssist is approved to treat certain patients with advanced heart failure who are undergoing percutaneous coronary interventions, such as stenting or balloon angioplasty, to reopen blocked coronary arteries, according to the company.
Seeking Alpha • Sep 28

Abiomed: Correction Offers Good Buying Opportunity

Summary Abiomed’s Impella range of micro heart pumps enjoy rising demand in the marketplace. The company’s OXY-1 System cardiopulmonary support device has strong growth prospect. The company’s revenue will grow at a CAGR of high-single digits in the long term, which will drive the company’s share price significantly higher in the next five years. Abiomed's (ABMD) micro heart pumps enjoy rising demand in the cardiovascular marketplace. I expect the company's Impella range of micro heart pumps will drive the company's long-term revenue growth significantly, and its Impella product pipeline will support long-term revenue growth as well. Long-term growth-oriented investors can buy the company's shares around the current price to maximize their profit. Abiomed develops heart pump products and oxygenation products for patients who are suffering from severe heart disease and in need of hemodynamic support. Its products are used in cath lab by interventional cardiologists and in the heart surgery suite by cardiac surgeons. The company's heart pump products work by improving blood flow and/or performing the pumping function of the heart. Its oxygenation products work by providing sufficient oxygenation to respiratory failure patients. Growth Drivers Impella Heart Pumps Abiomed's Impella micro heart pump product line is its main growth driver. Impella is a percutaneous heart pump that is used to treat CHD (coronary heart disease), and high-risk PCI (percutaneous coronary intervention). Impella has variants which are Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP. These pumps beat competitive products, such as intra-aortic balloon pumps (IABPs) and the TandemHeart device, due to the following reasons: Impella helps CHD and PCI patients maintain proper blood circulation in a better way. Impella offers continued function irrespective of timing or trigger. These pumps offer stability to patients despite the presence of arrhythmias. These pumps can pump up to 2.5 to 6 liters of blood per minute, which provides better cardiac output. According to a report: The heart pump device market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026. Promising product pipeline, increasing number of product approvals and emerging markets are expected to offer growth opportunities in the market during the forecast period. Due to the strong growth prospects of the heart pump market, Abiomed's revenue will continue to grow rapidly in the next five years. OXY-1 System Abiomed's OXY-1 System, which is a compact cardiopulmonary support system, is the company's another growth driver. The system offers respiratory assistance to patients suffering from cardiogenic shock combined with respiratory failure. The machine's oxygen concentrator and pump provide oxygenation to venous blood, and as a result, patients get significant respiratory support. The device performs well in the competitive environment and beat competitor products such as traditional ECMO (extracorporeal membrane oxygenation) machines due to its capability to provide uniform blood flow and superior respiratory support. I expect the device will support Abiomed's long-term revenue growth which primarily comes from Impella. Competition The heart pump industry is characterized by tremendous competition. Abiomed's competitors in this industry include Abbott Laboratories (ABT), Medtronic (MDT), Edwards Lifesciences (EW), Boston Scientific (BSX), LivaNova (LIVN), and Terumo Corporation (TRUMF). Abiomed competes with these companies on the basis of developing innovative heart pump devices, continuity in new product development, and advanced 24 x 7 hospital support. Abiomed's primary competitive advantage is that its current strategy of developing devices in the area of circulatory care is supported by substantial expertise in developing heart pump devices. As a result, the company's heart pump devices enjoy significant demand in the marketplace. The company intends to continue to use its expertise in developing additional circulatory support devices and making enhancements to existing devices, which will support its future revenue growth. The company's another competitive advantage is that its Impella micro heart pump is the only FDA approved heart pump for high-risk PCI, cardiogenic shock, and right ventricular failure. As a result, Impella and its forthcoming variants will continue to drive Abiomed's revenue growth. First Quarter 2023 Financial Results Abiomed reported first quarter 2023 revenue of $277 million, an increase of 10% year-over-year, compared to $253 million in the prior fiscal year period. Non-GAAP net income per diluted share came in at $1.25, an increase of 13.6% year-over-year, compared to $1.10 in the prior fiscal year period. The company delivered strong results for the first quarter of fiscal 2023. Top line grew driven by robust sales across the U.S., Europe and Japan. The company's heart pump product line is witnessing growing adoption since it addresses the challenge of treating heart disease in multiple emergency patient populations in the cath lab and surgical suite. This is driving the company's revenue growth. The company's bottom line grew driven by strong patient utilization across the three regions mentioned above. Abiomed 2.0, the new Abiomed with unparalleled focus on innovating heart and lung repairing devices amid hindrances such as hospital labor shortages, supply chain constraints and contrast media shortages, will boost the company's top and bottom line growth in the next five years. I expect the company's revenue will grow at a CAGR of high single-digits in this time frame.
Seeking Alpha • Sep 16

U.S. FDA gives two approvals to Abiomed Impella heart pumps

Abiomed (NASDAQ:ABMD) said on Friday it had received two approvals from the U.S. Food and Drug Administration related to clinical research of Impella heart pumps for acute myocardial infarction (AMI) cardiogenic shock or heart attack. The FDA has approved the on-label RECOVER IV trial for AMI cardiogenic shock patients. RECOVER IV is a trial that is designed to to achieve a Class I guideline recommendation for Impella use in AMI cardiogenic shock. The FDA has also approved and closed Impella’s prospective AMI cardiogenic shock post-approval study, dubbed Recover III. This study gathered real-world evidence on AMI cardiogenic shock patients treated with Impella between 2017–2019, collecting detailed data including stages of cardiogenic shock, cardiac output and timing of implantation.
Seeking Alpha • Aug 03

Abiomed FQ1 2023 Earnings Preview

Abiomed (NASDAQ:ABMD) is scheduled to announce FQ1 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $1.06 (-3.6% Y/Y) and the consensus Revenue Estimate is $276.46M (+9.4% Y/Y). Over the last 2 years, ABMD has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 1 upward revision and 1 downward.
Seeking Alpha • May 17

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

ABMD had a decent quarter where revenues grew nicely but profits languished due to sudden growth in R&D spend. Companies like ABMD have to expense R&D, which is not a problem, but a lack of profit growth isn't great given its valuation. The multiple doesn't offer much of a margin of safety, but we recognise the premier product portfolio. Overall, there is a defensive angle for the stock given rate increases, but the valuation is too much of a concern.
Seeking Alpha • Jan 24

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Abiomed is a company with a superb product in the mid-market space while what appears on the surface is an extremely high multiple. While the multiple appears high at first, it does actually reflect the profile of the company on a more normalised basis, where it is currently experiencing headwinds. The secular outlook is obviously intact, but given the high multiple and the unknown length of the medium-term headwinds, it is not an especially compelling opportunity.
Seeking Alpha • Sep 10

Abiomed: Impella Will Continue To Drive Revenue Growth

Abiomed’s strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company’s Impella range of micro heart pumps will continue to see increasing adoption globally. Long-term investors can buy the company’s shares around the current price to maximize their gain.
Seeking Alpha • Jul 13

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Abiomed has commenced its path to recovery on the charts, following a big hit in April this year. Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain traction sequentially as we walk through this year. Shares are trading at a premium to historical averages and to the peer group, thus balancing the investment case. Nonetheless, we are bullish on ABMD shares and see an investment debate that is skewed in investors' favour. Here, we present all of the necessary moving parts in the investment debate for the benefit of investors' own reasoning.

Shareholder Returns

ABMDUS Medical EquipmentUS Market
7D0.005%6.1%-3.3%
1Y8.2%-19.2%22.3%

Return vs Industry: ABMD exceeded the US Medical Equipment industry which returned -23.7% over the past year.

Return vs Market: ABMD exceeded the US Market which returned -22.8% over the past year.

Price Volatility

Is ABMD's price volatile compared to industry and market?
ABMD volatility
ABMD Average Weekly Movement14.6%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: ABMD's share price has been volatile over the past 3 months.

Volatility Over Time: ABMD's weekly volatility has increased from 9% to 15% over the past year.

About the Company

FoundedEmployeesCEOWebsite
19812,003Mike Minoguewww.abiomed.com

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.

Abiomed, Inc. Fundamentals Summary

How do Abiomed's earnings and revenue compare to its market cap?
ABMD fundamental statistics
Market capUS$17.19b
Earnings (TTM)US$266.76m
Revenue (TTM)US$1.07b
64.4x
P/E Ratio
16.0x
P/S Ratio

Is ABMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABMD income statement (TTM)
RevenueUS$1.07b
Cost of RevenueUS$200.59m
Gross ProfitUS$873.51m
Other ExpensesUS$606.74m
EarningsUS$266.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)5.91
Gross Margin81.32%
Net Profit Margin24.84%
Debt/Equity Ratio0%

How did ABMD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/24 09:06
End of Day Share Price 2022/12/21 00:00
Earnings2022/09/30
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abiomed, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lawrence NeiborBaird
Jan WaldBenchmark Company
Isaac RoGoldman Sachs